Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity: Growth Outlook Is Murky
Doximity remains a Hold as growth visibility weakens and NRR declines to 112%, raising concerns over future expansion. Engagement and profitability are robust, with workflow tools reaching 720,000 unique prescribers and GAAP gross margin near 90%. DOCS boasts a strong balance sheet, $735 million in cash, no debt, and ongoing share repurchases, supporting downside protection.
Doximity Stock Falls Despite Q3 Earnings & Revenues Beat Estimates
DOCS beats Q3 EPS and revenue estimates, but shares plunge 38.5% after hours as margins contract and FY26 revenue guidance is lowered.
Doximity, Inc. (DOCS) Q3 2026 Earnings Call Transcript
Doximity, Inc. (DOCS) Q3 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Doximity (DOCS) Q3 Earnings
While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Doximity (DOCS) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Doximity (DOCS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why Doximity (DOCS) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Doximity (DOCS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Doximity (DOCS) stood at $38.96, denoting a -3.56% move from the preceding trading day.
What Makes Doximity (DOCS) a New Strong Buy Stock
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Dr Martens sales growth slows but 'significant' profit increase still expected
Dr Martens PLC (LSE:DOCS) reported a decline in sales in the past quarter but said it is still on track to deliver "significant profit growth" in the current financial year. Revenues fell 3.1% to £253 million in the bootmaker's third quarter, worse than the 0.8% seen in the first half of the fiscal year.
3 Medical Info Systems Stocks to Gain From Digitization Despite Industry Woes
Medical Info Systems rides AI and telehealth tailwinds, lifting DOCS, TXG and OMCL, but cyber risks and industry underperformance keep optimism in check.
Here's Why Doximity (DOCS) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Doximity (DOCS) Ascends While Market Falls: Some Facts to Note
Doximity (DOCS) closed the most recent trading day at $46.49, moving +1.75% from the previous trading session.
